UBS Keeps Their Hold Rating on Humana (HUM)
UBS analyst maintained a Hold rating on Humana today and set a price target of $195.00.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
In addition to UBS, Humana also received a Hold from Truist Financial’s David S Macdonald in a report issued today. However, on the same day, Oppenheimer maintained a Buy rating on Humana (NYSE: HUM).
Based on Humana’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $32.65 billion and a net profit of $195 million. In comparison, last year the company earned a revenue of $29.4 billion and had a net profit of $480 million
Read More on HUM:
Disclaimer & DisclosureReport an Issue
- Humana price target lowered to $196 from $260 at BofA
- Humana price target lowered to $201 from $290 at Cantor Fitzgerald
- Humana price target lowered to $250 from $310 at Oppenheimer
- Humana price target lowered to $146 from $174 at Morgan Stanley
- Humana price target lowered to $252 from $312 at Guggenheim
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.